Painful Diabetic Peripheral Neuropathy: Practical Guidance and Challenges for Clinical Management

References

• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Price RS, Chen KS, Feldman EL. The importance of rare subtypes in diagnosis and treatment of peripheral neuropathy: a review. JAMA Neurol. 2015;72(12):1510–1518. doi:10.1001/jamaneurol.2015.2347
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin The. 2018;40(6):828–849. doi:10.1016/j.clinthera.2018.04.001
   Google Scholar
• Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. doi:10.2337/dc10-1303
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–638. doi:10.1002/dmrr.1225
   PubMed Web of Science ®Google Scholar
• Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747–787. doi:10.1016/j.ecl.2013.06.001
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, Hirsch AG, Brandenburg NA. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med. 2007;49(6):672–679. doi:10.1097/JOM.0b013e318065b83a
   PubMed Web of Science ®Google Scholar
• Alleman CJ, Westerhout KY, Hensen M, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015;109(2):215–225. doi:10.1016/j.diabres.2015.04.031
   PubMed Web of Science ®Google Scholar
• Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976–982. doi:10.1111/j.1464-5491.2004.01271.x
   PubMed Web of Science ®Google Scholar
• Sadosky A, Hopper J, Parsons B. Painful diabetic peripheral neuropathy: results of a survey characterizing the perspectives and misperceptions of patients and healthcare practitioners. Patient. 2014;7(1):107–114. doi:10.1007/s40271-013-0038-8
   PubMedGoogle Scholar
• Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923–1049. doi:10.1016/j.eprac.2022.08.002
   PubMed Web of Science ®Google Scholar
• UK National Screening Committee. Population screening explained. GOV.UK. Available from: https://www.gov.uk/guidance/population-screening-explained#:~:text=Screening%20is%20the%20process%20of,reduce%20associated%20problems%20or%20complications. Accessed August 2, 2023.
   Google Scholar
• Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20(1):26–33. doi:10.1016/j.jdiacomp.2005.09.007
   PubMed Web of Science ®Google Scholar
• Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006;29(4):883–887. doi:10.2337/diacare.29.04.06.dc05-2180
   PubMed Web of Science ®Google Scholar
• Petropoulos IN, Ponirakis G, Khan A, et al. Corneal confocal microscopy: ready for prime time. Clin Exp Optom. 2020;103(3):265–277. doi:10.1111/cxo.12887
   PubMed Web of Science ®Google Scholar
• Petropoulos IN, Bitirgen G, Ferdousi M, et al. Corneal confocal microscopy to image small nerve fiber degeneration: ophthalmology meets neurology. Front Pain Res. 2021;2:725363. doi:10.3389/fpain.2021.725363
   Google Scholar
• Alam U, Jeziorska M, Petropoulos IN, et al. Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy. PLoS One. 2017;12(7):e0180175. doi:10.1371/journal.pone.0180175
   PubMed Web of Science ®Google Scholar
• Preston FG, Meng Y, Burgess J, et al. Artificial intelligence utilising corneal confocal microscopy for the diagnosis of peripheral neuropathy in diabetes mellitus and prediabetes. Diabetologia. 2022;65(3):457–466. doi:10.1007/s00125-021-05617-x
   PubMed Web of Science ®Google Scholar
• Alam U, Ponirakis G, Asghar O, et al. Corneal confocal microscopy identifies people with type 1 diabetes with more rapid corneal nerve fibre loss and progression of neuropathy. J Clin Med. 2022;11(8). doi:10.3390/jcm11082249
   Web of Science ®Google Scholar
• Meng Y, Preston FG, Ferdousi M, et al. Artificial intelligence based analysis of corneal confocal microscopy images for diagnosing peripheral neuropathy: a binary classification model. J Clin Med. 2023;12(4):1284.
   PubMed Web of Science ®Google Scholar
• Alam U, Anson M, Meng Y, et al. Artificial intelligence and corneal confocal microscopy: the start of a beautiful relationship. J Clin Med. 2022;11(20):6199.
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Cash T, Davies J, et al. SUDOSCAN: a simple, rapid, and objective method with potential for screening for diabetic peripheral neuropathy. PLoS One. 2015;10(10):e0138224. doi:10.1371/journal.pone.0138224
   PubMed Web of Science ®Google Scholar
• Krishnan ST, Rayman G. The LDIflare: a novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care. 2004;27(12):2930–2935. doi:10.2337/diacare.27.12.2930
   PubMed Web of Science ®Google Scholar
• Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. doi:10.1038/s41572-019-0092-1
   PubMed Web of Science ®Google Scholar
• Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53–59. doi:10.1097/j.pain.0000000000001365
   PubMed Web of Science ®Google Scholar
• Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012;29(5):578–585. doi:10.1111/j.1464-5491.2011.03500.x
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–1920. doi:10.1185/030079906x132488
   PubMed Web of Science ®Google Scholar
• Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1(3):277–299. doi:10.1016/0304-3959(75)90044-5
   PubMed Web of Science ®Google Scholar
• Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology. 2022;98(1):31–43. doi:10.1212/wnl.0000000000013038
   PubMed Web of Science ®Google Scholar
• Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005;29(4):401–410. doi:10.1016/j.jpainsymman.2004.06.018
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497–508. doi:10.1089/dia.2005.7.497
   PubMedGoogle Scholar
• Kosinski M, Janagap CC, Gajria K, Schein J. Psychometric testing and validation of the Chronic Pain Sleep Inventory. Clin Ther. 2007;29:2562–2577. doi:10.1016/j.clinthera.2007.12.001
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi:10.1001/archpsyc.1961.01710120031004
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data. Springer; 2020. Copyright 2020, The Editor(s) (if applicable) and The Author(s). This book is an open access publication.
   Google Scholar
• D’Amato C, Morganti R, Di Gennaro F, Greco C, Marfia GA, Spallone V. A novel association between nondipping and painful diabetic polyneuropathy. Diabetes Care. 2014;37(9):2640–2642. doi:10.2337/dc14-0528
   PubMed Web of Science ®Google Scholar
• Gandhi RA, Marques JL, Selvarajah D, Emery CJ, Tesfaye S. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Diabetes Care. 2010;33(7):1585–1590. doi:10.2337/dc09-2314
   PubMed Web of Science ®Google Scholar
• Spallone V, Morganti R, D’Amato C, et al. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. Eur J Pain. 2011;15(2):153–160. doi:10.1016/j.ejpain.2010.06.011
   PubMed Web of Science ®Google Scholar
• Hansen CS, Jensen TM, Jensen JS, et al. The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study. Diabet Med. 2015;32(6):778–785. doi:10.1111/dme.12753
   PubMed Web of Science ®Google Scholar
• Krämer HH, Rolke R, Bickel A, Birklein F. Thermal thresholds predict painfulness of diabetic neuropathies. Diabetes Care. 2004;27(10):2386–2391. doi:10.2337/diacare.27.10.2386
   PubMed Web of Science ®Google Scholar
• Ziegler D, Tesfaye S, Spallone V, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Res Clin Pract. 2022;186:109063. doi:10.1016/j.diabres.2021.109063
   PubMed Web of Science ®Google Scholar
• Alvarez M, Sierra OR, Saavedra G, Moreno S. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. Endocrine Connections. 2019;8(10):1324–1329. doi:10.1530/ec-19-0382
   PubMed Web of Science ®Google Scholar
• Ashley JM. Chapter Two - Manifestations and Measurement of Food Insecurity. In: Ashley JM, editor. Food Security in the Developing World. Academic Press; 2016:19–38.
   Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(4Suppl):S12–25. doi:10.1016/s0025-6196(11)61475-4
   PubMedGoogle Scholar
• Edwards RR. Chapter 5 - Pain Assessment. In: Benzon HT, Raja SN, Molloy RE, Liu SS, Fishman SM, editors. Essentials of Pain Medicine and Regional Anesthesia (Second Edition). Churchill Livingstone; 2005:29–34.
   Google Scholar
• Delgado DA, Lambert BS, Boutris N, et al. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. J Am Acad Orthop Surg Glob Res Rev. 2018;2(3):e088. doi:10.5435/JAAOSGlobal-D-17-00088
   PubMedGoogle Scholar
• Rosseland R, Pallesen S, Nordhus IH, Matre D, Blågestad T. Effects of sleep fragmentation and induced mood on pain tolerance and pain sensitivity in young healthy adults. Front Psychol. 2018;9:2089. doi:10.3389/fpsyg.2018.02089
   PubMed Web of Science ®Google Scholar
• Tang NKY, Salkovskis PM, Hodges A, Wright KJ, Hanna M, Hester J. Effects of mood on pain responses and pain tolerance: an experimental study in chronic back pain patients. Pain. 2008;138(2):392–401. doi:10.1016/j.pain.2008.01.018
   PubMed Web of Science ®Google Scholar
• Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. doi:10.1007/s11892-014-0528-7
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6(6):Cd007543. doi:10.1002/14651858.CD007543.pub2
   PubMedGoogle Scholar
• Gouveri E, Papanas N. The emerging role of continuous glucose monitoring in the management of diabetic peripheral neuropathy: a narrative review. Diabetes Ther. 2022;13(5):931–952. doi:10.1007/s13300-022-01257-5
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. doi:10.1016/s0140-6736(10)60576-4
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117. doi:10.1016/0168-8227(95)01064-k
   PubMed Web of Science ®Google Scholar
• Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–1461. doi:10.2337/diab.38.11.1456
   PubMed Web of Science ®Google Scholar
• Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55(5):1463–1469. doi:10.2337/db05-1423
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350. doi:10.1056/NEJMoa032782
   PubMed Web of Science ®Google Scholar
• Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634–1640. doi:10.2337/db08-1771
   PubMed Web of Science ®Google Scholar
• Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51(4):562–566. doi:10.1007/s00125-007-0919-2
   PubMed Web of Science ®Google Scholar
• Villegas-Rivera G, Román-Pintos LM, Cardona-Muñoz EG, et al. Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid Med Cell Longev. 2015;2015:756294. doi:10.1155/2015/756294
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Bashir B, Ferdousi M, et al. Lipids and peripheral neuropathy. Curr Opin Lipidol. 2021;32(4):249–257. doi:10.1097/mol.0000000000000770
   PubMed Web of Science ®Google Scholar
• Kluding PM, Pasnoor M, Singh R, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012;26(5):424–429. doi:10.1016/j.jdiacomp.2012.05.007
   PubMed Web of Science ®Google Scholar
• Yoo M, D’Silva LJ, Martin K, et al. Pilot study of exercise therapy on painful diabetic peripheral neuropathy. Pain Med. 2015;16(8):1482–1489. doi:10.1111/pme.12743
   PubMed Web of Science ®Google Scholar
• Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–1299. doi:10.2337/dc06-0224
   PubMed Web of Science ®Google Scholar
• Amato Nesbit S, Sharma R, Waldfogel JM, et al. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2019;35(1):15–25. doi:10.1080/03007995.2018.1497958
   PubMed Web of Science ®Google Scholar
• Naderi Nabi B, Sedighinejad A, Haghighi M, et al. Comparison of transcutaneous electrical nerve stimulation and pulsed radiofrequency sympathectomy for treating painful diabetic neuropathy. Anesth Pain Med. 2015;5(5):e29280. doi:10.5812/aapm.29280
   PubMedGoogle Scholar
• Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness. J Pain. 2003;4(3):109–121. doi:10.1054/jpai.2003.434
   PubMed Web of Science ®Google Scholar
• Crasto W, Altaf QA, Selvaraj DR, et al. Frequency Rhythmic Electrical Modulation System (FREMS) to alleviate painful diabetic peripheral neuropathy: a pilot, randomised controlled trial (The FREMSTOP study). Diabet Med. 2022;39(3):e14710. doi:10.1111/dme.14710
   PubMed Web of Science ®Google Scholar
• Bosi E, Bax G, Scionti L, et al. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial. Diabetologia. 2013;56(3):467–475. doi:10.1007/s00125-012-2795-7
   PubMed Web of Science ®Google Scholar
• Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005;48(5):817–823. doi:10.1007/s00125-005-1734-2
   PubMed Web of Science ®Google Scholar
• Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol. 2021;78(6):687–698. doi:10.1001/jamaneurol.2021.0538
   PubMed Web of Science ®Google Scholar
• Duarte RV, Nevitt S, Copley S, et al. Systematic review and network meta-analysis of neurostimulation for painful diabetic neuropathy. Diabetes Care. 2022;45(10):2466–2475. doi:10.2337/dc22-0932
   PubMed Web of Science ®Google Scholar
• de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155(11):2426–2431. doi:10.1016/j.pain.2014.08.031
   PubMed Web of Science ®Google Scholar
• Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684
   PubMed Web of Science ®Google Scholar
• van Beek M, Slangen R, Schaper NC, et al. Sustained treatment effect of spinal cord stimulation in painful diabetic peripheral neuropathy: 24-month follow-up of a prospective two-center randomized controlled trial. Diabetes Care. 2015;38(9):e132–4. doi:10.2337/dc15-0740
   PubMed Web of Science ®Google Scholar
• Eldabe S, Buchser E, Duarte RV. Complications of spinal cord stimulation and peripheral nerve stimulation techniques: a review of the literature. Pain Med. 2016;17(2):325–336. doi:10.1093/pm/pnv025
   PubMed Web of Science ®Google Scholar
• Arnall DA, Nelson AG, López L, et al. The restorative effects of pulsed infrared light therapy on significant loss of peripheral protective sensation in patients with long-term type 1 and type 2 diabetes mellitus. Acta Diabetol. 2006;43(1):26–33. doi:10.1007/s00592-006-0207-5
   PubMed Web of Science ®Google Scholar
• Leonard DR, Farooqi MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. Diabetes Care. 2004;27(1):168–172. doi:10.2337/diacare.27.1.168
   PubMed Web of Science ®Google Scholar
• Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care. 2008;31(2):316–321. doi:10.2337/dc07-1794
   PubMed Web of Science ®Google Scholar
• Rastogi A, Uppula P, Saikia U, Bhansali A. Effect of monochromatic infrared energy on quality of life and intraepidermal nerve fiber density in painful diabetic neuropathy: a randomized, sham control study. Neurol India. 2021;69(5):1331–1337. doi:10.4103/0028-3886.329614
   PubMed Web of Science ®Google Scholar
• Twiddy H, Frank B, Alam U. A Consideration of the psychological aspects to managing patients with painful diabetic neuropathy: an insight into pain management services at a tertiary centre in the UK. Diabetes Ther. 2021;12(2):487–498. doi:10.1007/s13300-020-00983-y
   PubMed Web of Science ®Google Scholar
• Williams ACC, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. 2020;8(8):Cd007407. doi:10.1002/14651858.CD007407.pub4
   PubMedGoogle Scholar
• Otis JD, Sanderson K, Hardway C, Pincus M, Tun C, Soumekh S. A randomized controlled pilot study of a cognitive-behavioral therapy approach for painful diabetic peripheral neuropathy. J Pain. 2013;14(5):475–482. doi:10.1016/j.jpain.2012.12.013
   PubMed Web of Science ®Google Scholar
• Bril V, Breiner A, Perkins BA, Zochodne D. Neuropathy. Can J Diabetes. 2018;42:S217–s221. doi:10.1016/j.jcjd.2017.10.028
   PubMed Web of Science ®Google Scholar
• Ziegler D, Keller J, Maier C, Pannek J. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2021;129(S01):S70–s81. doi:10.1055/a-1284-6245
   PubMedGoogle Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/s1474-4422(14)70251-0
   PubMed Web of Science ®Google Scholar
• Moisset X, Bouhassira D, Avez Couturier J, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176(5):325–352. doi:10.1016/j.neurol.2020.01.361
   PubMed Web of Science ®Google Scholar
• NICE CfCPa. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. 2013.
   Google Scholar
• Sloan G, Alam U, Selvarajah D, Tesfaye S. The treatment of painful diabetic neuropathy. Curr Diabetes Rev. 2022;18(5):e070721194556. doi:10.2174/1573399817666210707112413
   PubMed Web of Science ®Google Scholar
• Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142(1–2):13–16. doi:10.1016/j.pain.2008.11.019
   PubMed Web of Science ®Google Scholar
• Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):Cd007076. doi:10.1002/14651858.CD007076.pub3
   PubMed Web of Science ®Google Scholar
• Dy SM, Bennett WL, Sharma R, et al. AHRQ Comparative Effectiveness Reviews. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy. Agency for Healthcare Research and Quality (US); 2017.
   Google Scholar
• Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2021;10(1):55–68. doi:10.1007/s40122-020-00210-3
   PubMed Web of Science ®Google Scholar
• Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6. doi:10.1186/1471-2377-9-6
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167–184. doi:10.1111/papr.12054
   PubMed Web of Science ®Google Scholar
• Vilar S, Castillo JM, Munuera Martínez PV, Reina M, Pabón M. Therapeutic alternatives in painful diabetic neuropathy: a meta-analysis of randomized controlled trials. Korean J Pain. 2018;31(4):253–260. doi:10.3344/kjp.2018.31.4.253
   PubMed Web of Science ®Google Scholar
• Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 2017;88(20):1958–1967. doi:10.1212/wnl.0000000000003882
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):Cd007938. doi:10.1002/14651858.CD007938.pub4
   PubMedGoogle Scholar
• Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropathy: current and developmental drugs. Drugs. 2020;80(4):363–384. doi:10.1007/s40265-020-01259-2
   PubMed Web of Science ®Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–748. doi:10.1038/sj.bjp.0707253
   PubMed Web of Science ®Google Scholar
• Benbouzid M, Gavériaux-Ruff C, Yalcin I, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry. 2008;63(6):633–636. doi:10.1016/j.biopsych.2007.06.016
   PubMed Web of Science ®Google Scholar
• Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639–649. doi:10.7326/m14-0511
   PubMed Web of Science ®Google Scholar
• Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;1(1):Cd011209. doi:10.1002/14651858.CD011209.pub2
   PubMedGoogle Scholar
• Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:Cd007115. doi:10.1002/14651858.CD007115.pub3
   PubMed Web of Science ®Google Scholar
• Markovits E, Gilhar A. Capsaicin--an effective topical treatment in pain. Int J Dermatol. 1997;36(6):401–404. doi:10.1046/j.1365-4362.1997.00102.x
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. doi:10.1016/j.jpain.2016.09.008
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251. doi:10.1186/s12883-016-0752-7
   PubMed Web of Science ®Google Scholar
• Anand P, Privitera R, Donatien P, et al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Front Neurol. 2022;13:998904. doi:10.3389/fneur.2022.998904
   PubMed Web of Science ®Google Scholar
• Martini C, Yassen A, Olofsen E, Passier P, Stoker M, Dahan A. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res. 2012;5:51–59. doi:10.2147/jpr.S30406
   PubMedGoogle Scholar
• Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61(6):914–918. doi:10.1001/archneur.61.6.914
   PubMedGoogle Scholar
• Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(Suppl 2):S21–8. doi:10.1185/030079904x12960
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663–1676. doi:10.1185/03007990903047880
   PubMed Web of Science ®Google Scholar
• Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014(7):Cd010958. doi:10.1002/14651858.CD010958.pub2
   PubMedGoogle Scholar
• Agrawal R, Goswami J, Jain S and Kochar D. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pr. 2009;83(3):371–378. doi:10.1016/j.diabres.2008.12.018
   PubMed Web of Science ®Google Scholar
• Agrawal R, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: A randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pr. 2007;77(2):161–167. doi:10.1016/j.diabres.2006.12.003
   PubMed Web of Science ®Google Scholar
• Yuen KC, Baker NR, Rayman G. Treatment of Chronic Painful Diabetic Neuropathy with Isosorbide Dinitrate Spray. Diabetes Care. 2002;25(10):1699–1703. doi:10.2337/diacare.25.10.1699
   PubMed Web of Science ®Google Scholar
• Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9(9):Cd012329. doi:10.1002/14651858.Cd012329
   PubMedGoogle Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625. doi:10.1016/j.pain.2013.05.043
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. 2022;400(10353):680–690. doi:10.1016/s0140-6736(22)01472-6
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Sloan G, Petrie J, et al. Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT. Health Technol Assess. 2022;26(39):1–100. doi:10.3310/rxuo6757
   PubMed Web of Science ®Google Scholar
• Iacob E, Hagn EE, Sindt J, et al. Tertiary Care Clinical Experience with Intravenous Lidocaine Infusions for the Treatment of Chronic Pain. Pain Med. 2018;19(6):1245–1253. doi:10.1093/pm/pnx167
   PubMed Web of Science ®Google Scholar
• Kim YC, Castañeda AM, Lee CS, Jin HS, Park KS, Moon JY. Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, double-blind, and placebo-controlled study. Reg Anesth Pain Med. 2018;43(4):415–424. doi:10.1097/aap.0000000000000741
   PubMed Web of Science ®Google Scholar
• Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5(4):209–227. doi:10.1006/nbdi.1998.0204
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155(11):2263–2273. doi:10.1016/j.pain.2014.08.014
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Finnerup NB, et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. Pain. 2015;156(11):2234–2244. doi:10.1097/j.pain.0000000000000266
   PubMed Web of Science ®Google Scholar
• Wilkinson ID, Teh K, Heiberg-Gibbons F, et al. Determinants of treatment response in painful diabetic peripheral neuropathy: a combined deep sensory phenotyping and multimodal brain MRI study. Diabetes. 2020;69(8):1804–1814. doi:10.2337/db20-0029
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–1823. doi:10.1016/j.pain.2012.04.014
   PubMed Web of Science ®Google Scholar
• González-Duarte A, Lem M, Díaz-Díaz E, Castillo C, Cárdenas-Soto K. The efficacy of pregabalin in the treatment of prediabetic neuropathic pain. Clin J Pain. 2016;32(11):927–932. doi:10.1097/ajp.0000000000000339
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Wilkinson ID, Fang F, et al. Structural and functional abnormalities of the primary somatosensory cortex in diabetic peripheral neuropathy: a multimodal MRI study. Diabetes. 2019;68(4):796–806. doi:10.2337/db18-0509
   PubMed Web of Science ®Google Scholar
• Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113(1):148–156. doi:10.1093/bja/aeu056
   PubMed Web of Science ®Google Scholar
• Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153(6):1193–1198. doi:10.1016/j.pain.2012.02.021
   PubMed Web of Science ®Google Scholar
• Lee-Kubli C, Marshall AG, Malik RA, Calcutt NA. The H-reflex as a biomarker for spinal disinhibition in painful diabetic neuropathy. Curr Diab Rep. 2018;18(1):1. doi:10.1007/s11892-018-0969-5
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhu Y, Wang Z, et al. Rate-dependent depression: a predictor of the therapeutic efficacy in treating painful diabetic peripheral neuropathy. Diabetes. 2022;71(6):1272–1281. doi:10.2337/db21-0960
   PubMed Web of Science ®Google Scholar
• Forstenpointner J, Otto J, Baron R. Individualized neuropathic pain therapy based on phenotyping: are we there yet? Pain. 2018;159(3):569–575. doi:10.1097/j.pain.0000000000001088
   PubMed Web of Science ®Google Scholar
• Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007;12(1):113–126. doi:10.1517/14728214.12.1.113
   PubMed Web of Science ®Google Scholar
• Shaibani AI, Pope LE, Thisted R, Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med. 2012;13(2):243–254. doi:10.1111/j.1526-4637.2011.01316.x
   PubMed Web of Science ®Google Scholar
• Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014;7:339–351. doi:10.2147/jpr.S55682
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657–665. doi:10.1124/jpet.106.103382
   PubMed Web of Science ®Google Scholar
• Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled Phase 2 clinical trial. Lancet. 2014;383(9929):1637–1647. doi:10.1016/s0140-6736(13)62337-5
   PubMed Web of Science ®Google Scholar
• Anand U, Yiangou Y, Sinisi M, et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015;11:38. doi:10.1186/s12990-015-0038-x
   PubMed Web of Science ®Google Scholar
• Liu Y, Luo B, Han F, et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One. 2014;9(3):e90942. doi:10.1371/journal.pone.0090942
   PubMed Web of Science ®Google Scholar
• Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: integration between immune system and nociception. Peptides. 2016;76:73–79. doi:10.1016/j.peptides.2016.01.003
   PubMed Web of Science ®Google Scholar
• Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20(1):658–666. doi:10.2119/molmed.2014.00215
   PubMedGoogle Scholar
• Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2017;58(6):Bio52–bio60. doi:10.1167/iovs.16-21291
   PubMed Web of Science ®Google Scholar
• Jain SM, Balamurugan R, Tandon M, et al. Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function. Pain. 2022;163(6):e738–e747. doi:10.1097/j.pain.0000000000002470
   PubMed Web of Science ®Google Scholar
• Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16(6):1163–1176. doi:10.1111/pme.12677
   PubMed Web of Science ®Google Scholar
• Bernier LP, Ase AR, Séguéla P. P2X receptor channels in chronic pain pathways. Br J Pharmacol. 2018;175(12):2219–2230. doi:10.1111/bph.13957
   PubMed Web of Science ®Google Scholar
• Jarvis MF, Burgard EC, McGaraughty S, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A. 2002;99(26):17179–17184. doi:10.1073/pnas.252537299
   PubMed Web of Science ®Google Scholar
• Rao S, Liu S, Zou L, et al. The effect of sinomenine in diabetic neuropathic pain mediated by the P2X(3) receptor in dorsal root ganglia. Purinergic Signal. 2017;13(2):227–235. doi:10.1007/s11302-016-9554-z
   PubMed Web of Science ®Google Scholar
• Rastogi A, Jude EB. Novel treatment modalities for painful diabetic neuropathy. Diabetes Metab Syndr. 2021;15(1):287–293. doi:10.1016/j.dsx.2021.01.004
   PubMed Web of Science ®Google Scholar
• Kopsky DJ, Hesselink JM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract. 2012;12(2):148–153. doi:10.1111/j.1533-2500.2011.00477.x
   PubMed Web of Science ®Google Scholar
• Mahoney JM, Vardaxis V, Moore JL, Hall AM, Haffner KE, Peterson MC. Topical ketamine cream in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc. 2012;102(3):178–183. doi:10.7547/1020178
   PubMed Web of Science ®Google Scholar
• Ali G, Subhan F, Abbas M, Zeb J, Shahid M, Sewell RD. A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(11):1129–1140. doi:10.1007/s00210-015-1145-y
   PubMed Web of Science ®Google Scholar
• Alam U, Arul-Devah V, Javed S, Malik RA. Vitamin D and diabetic complications: true or false prophet? Diabetes Ther. 2016;7(1):11–26. doi:10.1007/s13300-016-0159-x
   PubMed Web of Science ®Google Scholar
• Lv WS, Zhao WJ, Gong SL, et al. Serum 25-hydroxyvitamin D levels and peripheral neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis. J Endocrinol Invest. 2015;38(5):513–518. doi:10.1007/s40618-014-0210-6
   PubMed Web of Science ®Google Scholar
• Alam U, Petropoulos IN, Ponirakis G, et al. Vitamin D deficiency is associated with painful diabetic neuropathy. Diabetes Metab Res Rev. 2021;37(1):e3361. doi:10.1002/dmrr.3361
   PubMed Web of Science ®Google Scholar
• Basit A, Basit KA, Fawwad A, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care. 2016;4(1):e000148. doi:10.1136/bmjdrc-2015-000148
   PubMed Web of Science ®Google Scholar
• Alam U, Fawwad A, Shaheen F, Tahir B, Basit A, Malik RA. Improvement in neuropathy specific quality of life in patients with diabetes after vitamin D supplementation. J Diabetes Res. 2017;2017:7928083. doi:10.1155/2017/7928083
   PubMed Web of Science ®Google Scholar